Literature DB >> 7958480

Recombinant vector vaccines in vaccinology.

M R Hilleman1.   

Abstract

The development of recombinant vector vaccines will be guided by nearly two centuries of research in vaccinology and immunology. Experimental vector vaccines may be of viral, bacterial or genetic composition and their acceptability will depend on safety, efficacy, and practicality as seen by the user, the developer, and the licensing authority. Recombinant vector vaccines will need to compete with alternative vaccine approaches and may find special use for non-propagable agents, immunization in early life, fertility control, and emerging infectious agents. Needs of the developing nations that include low cost, temperature stability, and ease of administration may be met, in part at least, by the vector vaccine approach.

Mesh:

Substances:

Year:  1994        PMID: 7958480

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  4 in total

Review 1.  Developing mRNA-vaccine technologies.

Authors:  Thomas Schlake; Andreas Thess; Mariola Fotin-Mleczek; Karl-Josef Kallen
Journal:  RNA Biol       Date:  2012-10-12       Impact factor: 4.652

Review 2.  mRNA vaccine delivery using lipid nanoparticles.

Authors:  Andreas M Reichmuth; Matthias A Oberli; Ana Jaklenec; Robert Langer; Daniel Blankschtein
Journal:  Ther Deliv       Date:  2016

Review 3.  Viral vectors for veterinary vaccines.

Authors:  M Sheppard
Journal:  Adv Vet Med       Date:  1999

4.  An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose.

Authors:  Kakon Nag; Juwel Chandra Baray; Maksudur Rahman Khan; Asif Mahmud; Jikrul Islam; Sanat Myti; Rostum Ali; Enamul Haq Sarker; Samir Kumar; Mobarak Hossain Chowdhury; Rony Roy; Faqrul Islam; Uttam Barman; Habiba Khan; Sourav Chakraborty; Alam Badsha; Manik Hossain; Shamim Ahammad; Mashfiqur Rahman Chowdhury; Polash Ghosh; Rayhanul Islam Shimul; Ronzu Ahmmed; Eleus Hussain Bhuiya; Bipul Kumar Biswas; Mohammad Mohiuddin; Naznin Sultana
Journal:  Vaccine       Date:  2021-05-18       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.